DESOXIMETASONE- desoximetasone ointment Padagis Israel Pharmaceuticals Ltd

Desoximetasone Ointment USP, 0.25%

For Topical Use Only. Not For Oral, Ophthalmic, or Intravaginal Use.

Rx Only

DESCRIPTION


Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

Each gram of Desoximetasone Ointment USP, 0.25% contains 2.5 mg of desoximetasone in an ointment base consisting of fractionated coconut oil and white petrolatum.

The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-, $(11\beta,16\alpha)$ -.

Desoximetasone has the molecular formula $C_{22}H_{29}FO_4$ and a molecular weight of 376.47. The CAS Registry Number is 382-67-2.

The structural formula is:



CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics -

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Pharmacokinetic studies in men with desoximetasone ointment USP, 0.25% with tagged desoximetasone showed no detectable level (limit of sensitivity: 0.003 μ g/mL) in 1 subject and 0.004 and 0.006 μ g/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces. Seven days after application, no further radioactivity was detected in urine or feces. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.

INDICATIONS AND USAGE

Desoximetasone ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Desoximetasone ointment USP, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

WARNINGS

Keep out of reach of children.

PRECAUTIONS

General -

Systemic absorption of topical corticosteroids can produce reversible hypothalamicpituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.

Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids.

Local Adverse Reactions with Topical Corticosteroids

Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.

Allergic Contact Dermatitis with Topical Corticosteroids

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

Concomitant Skin Infections

Concomitant skin infections should be treated with an appropriate antimicrobial agent.

If the infection persists, desoximetasone ointment USP, 0.25% should be discontinued until the infection has been adequately treated.

Information for the Patient

Patients using topical corticosteroids should receive the following information and instructions:

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
- 4. Patients should report any signs of local adverse reactions, especially under occlusive dressings.
- 5. Other corticosteroid-containing products should not be used with desoximetasone ointment USP, 0.25% without first consulting with the physician. As with other corticosteroids, therapy should be discontinued when control is achieved.

If no improvement is seen within 4 weeks, contact the physician.

Laboratory Tests

The following tests may be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis suppression:

Urinary free cortisol test

ACTH stimulation test

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Desoximetasone was nonmutagenic in the Ames test.

Pregnancy. Teratogenic Effects. Pregnancy Category C

Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone ointment USP, 0.25%.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone ointment USP, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers -

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use -

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the

least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients. Safety and effectiveness of desoximetasone ointment USP, 0.25% in pediatric patients below the age of 10 have not been established.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings.

These reactions are listed in an approximate decreasing order of occurrence:

Burning	Hypertrichosis	Maceration of the skin
Itching	Acneiform eruptions	Secondary infection
Irritation	Hypopigmentation	Skin atrophy
Dryness	Perioral dermatitis	Striae
Folliculitis	Allergic contact dermatitis	Miliaria

In controlled clinical studies the incidence of adverse reactions was low (0.3%) for desoximetasone ointment USP, 0.25% and consisted of development of comedones at the site of application.

To report SUSPECTED ADVERSE REACTIONS, contact Padagis[®] at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS**).

DOSAGE AND ADMINISTRATION

Apply a thin film of desoximetasone ointment USP, 0.25% to the affected skin areas twice daily. Rub in gently.

HOW SUPPLIED

Desoximetasone Ointment USP, 0.25% is supplied as follows:

15 gram tube (NDC 45802-496-14)

60 gram tube (NDC 45802-**496**-96)

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Manufactured By Padagis®

Yeruham, Israel

Distributed By

Padagis[®] Allegan, MI 49010 • www.padagis.com Rev 12-22 4N400 RC J4

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- 15 g CARTON

NDC 45802-496-14

Rx Only

Desoximetasone Ointment USP, 0.25%

For Topical Use Only. Not For Oral, Ophthalmic, or Intravaginal Use.

NET WT 15 g

Keep this and all medications out of the reach of children.



The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

S/N [insert product's serial number] Lot [insert product's lot number] Exp [insert product's expiration date]

de	E SOXIMET soximetasone	ointment							
Ρ	roduct Infor	mation							
Product Type			HUMAN PRESCRIPTION DRUG		ltem Coo	em Code (Source)		NDC:45802-496	
Re	oute of Admini	stration	TOPICAL						
Δ.	tivo Logradi		Maiah/						
A	ctive Ingredi		-			Basis	of		
Ingro			edient Name			Strength		Strength	
DESOXIMETASONE (UNII: 4E07GX UNII: 4E07GXB7AU)			B7AU) (DESOXIMETASONE -	ASONE - DESO		DESOXIMETAS	SOXIMETASONE		
In	active Ingre	dients							
Ingredient Name							Strength		
			-					Strength	
	TROLATUM (UNI							Strength	
			-					Strength	
MI								Strength	
МІ	EDIUM-CHAIN TF	RIGLYCERIDES				ng Start ate	Ma	Strength rketing End Date	
Р	EDIUM-CHAIN TR	RIGLYCERIDES	(UNII: C9H2L21V7U) kage Description				Ma	rketing End	
мі Ра	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496-	RIGLYCERIDES Pac 1 in 1 CARTON	(UNII: C9H2L21V7U) kage Description		Da		Ma	rketing End	
мі Ра # 1	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496-	Pac 1 in 1 CARTON 15 g in 1 TUBE Product	(UNII: C9H2L21V7U) kage Description ; Type 0: Not a Combination	05	Da		Ma	rketing End	
мі Р а # 1	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496- 14	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON	(UNII: C9H2L21V7U) kage Description ; Type 0: Not a Combination	05	D a		Ma	rketing End	
МІ Р а 1 1 2	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496- 14	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 60 g in 1 TUBE	(UNII: C9H2L21V7U) kage Description ; Type 0: Not a Combination	05	D a		Ma	rketing End	
МІ # 1 2 2	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496- 14	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 60 g in 1 TUBE Product	(UNII: C9H2L21V7U) Kage Description E; Type 0: Not a Combination E; Type 0: Not a Combination	05	D a		Ma	rketing End	
МІ # 1 2 2	EDIUM-CHAIN TR Ackaging Item Code NDC:45802-496- 14 NDC:45802-496- 96	Pac 1 in 1 CARTON 15 g in 1 TUBE Product 1 in 1 CARTON 60 g in 1 TUBE Product	(UNII: C9H2L21V7U) Kage Description E; Type 0: Not a Combination E; Type 0: Not a Combination	05	Da /14/2015 5/16/2015 Marke			rketing End	

Labeler - Padagis Israel Pharmaceuticals Ltd (600093611)

Revised: 12/2022

Padagis Israel Pharmaceuticals Ltd